MADISON, Wis. (PRWEB) March 03, 2015
Quincy Bioscience, a Wisconsin-based biotech company, announces that its headquarters, shipping, and manufacturing locations have all been recertified as Good Manufacturing Practices (GMP) facilities registered by NSF International for 2015.
Earning GMP registration from NSF International verifies that Quincy Bioscience’s facilities have the proper methods, equipment, facilities, and controls in place for producing dietary supplement products. The NSF GMPs were developed in accordance with the U.S. Food and Drug Administration’s (FDA) 21 CFR part 111 regulation on dietary supplement manufacturing, packaging, and distribution. Utilizing GMP guidelines assists companies in developing and maintaining proper controls in their manufacturing process so that products are processed, manufactured and labeled in a consistent manner, and meet quality standards.
“It is important to stay on top of our GMP responsibilities and the third-party certification process with NSF has helped us stay focused on product safety and manufacturing practices,” said Mark Underwood, president and co-founder of Quincy Bioscience.
Quincy Bioscience manufactures Prevagen, the No. 1 selling brain health supplement in chain drug stores. Prevagen contains the main ingredient “apoaequorin,” a protein originally discovered in a jellyfish which is used to improve mild memory loss associated with aging.
For more information, please visit http://www.quincybioscience.com.
About Quincy Bioscience:
Quincy Bioscience is a biotechnology company based in Madison, Wis. that focuses on the discovery, development and commercialization of novel technologies to support good health in aging. The company’s products focus on supporting memory and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health.